Keese Kyle 4
4 · Emergent BioSolutions Inc. · Filed Aug 25, 2010
Insider Transaction Report
Form 4
Keese Kyle
SVP, Mfg Ops
Transactions
- Other
Common Stock
2010-05-27+5,276→ 14,346 total - Sale
Common Stock
2010-08-18$17.50/sh−5,276$92,330→ 9,070 total
Footnotes (1)
- [F1]In-kind pro rata distribution from BioPharm, L.L.C., of which the reporting person is a non-managing member, for no consideration.